The Claim

Visual interpretation of tau-PET scans using FDA/EMA-approved criteria underestimates the prevalence of early tau pathology in individuals with elevated plasma p-tau217, and semi-quantitative or ordinal staging is required for accurate risk stratification.

Source: Clinico-biological trajectories stratified by combined tau biomarkers in preclinical Alzheimer’s disease

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
65score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Description
1 study reviewed
In plain English

When doctors visually read tau-PET brain scans using standard criteria, they may fail to detect early tau buildup in people with high levels of p-tau217 in their blood, and more precise measurement methods are needed to correctly identify those at risk.

See the scientific wording

Visual interpretation of tau-PET scans using FDA/EMA-approved criteria may miss early tau pathology in individuals with elevated plasma p-tau217, suggesting that binary classification underestimates the prevalence of early tau and that semi-quantitative or ordinal staging is needed for accurate risk stratification.

Why this might work

Amyloid buildup in the brain triggers tau proteins to become abnormally phosphorylated at a specific site, releasing this modified tau into the bloodstream. This happens before tau forms clumps visible on brain scans. Visual scans only detect tau when it has clumped into dense, advanced tangles, so they miss the early stage where phosphorylated tau is present in the blood but not yet visible in the brain. This causes the scans to falsely appear negative even when Alzheimer's pathology has already started.

Verified mechanismbased on 1 study

What the research says

1 study
  1. Study: Clinico-biological trajectories stratified by combined tau biomarkers in preclinical Alzheimer’s disease

    Some people have early signs of tau buildup in their blood, but their brain scans don't show it yet because the scans only say 'yes' or 'no' for tau. This study says those scans are too simple—they miss early warning signs—and we need better, more detailed scans to catch Alzheimer's risk earlier.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.